Defining purpose: A key step in genetic test evaluation

Genetics in Medicine

Volumn 9, Issue 10, 2007, Pages 675-681

  Burke, Wylie ^a   Zimmern, Ronald L ^b   Kroese, Mark ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC PROCEDURE; FUNDING; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HEALTH CARE; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MORBIDITY; MORTALITY; NOTE; ONCOGENE; OUTCOME ASSESSMENT; PHENYLKETONURIA; PRACTICE GUIDELINE;

DECISION MAKING; DELIVERY OF HEALTH CARE; GENETIC SCREENING; HUMANS;

EID: 37349055390     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318156e45b     Document Type: Note

References (45)

1. Zimmern R, Kroese M. The evaluation of genetic tests. J Public Health. 2007;29: 246-250.
2. Secretary's Advisory Committee on Genetic Testing. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT, July 2000. National Institutes of Health (NIH). Available at: http://www4.od.nih.gov/oba/sacgt/ reports/oversight_report.pdf Accessed June 15, 2007.
3. Burke W, Atkins D, Gwinn M, Guttmacher A, et al. Genetic test evaluation: information needs of clinicians, policy-makers and the public. Am J Epidemiol 2002;156: 311-318.
4. Haddow J, Palomaki G. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human genome epidemiology. Oxford: Oxford University Press, 2004:217-233.
5. Kroese M, Zimmern RL, Sanderson S. Genetic tests and their evaluation: can we answer the key questions? Genet Med 2004;6:475-480.
6. National Office of Public Health Genomics. Evaluation of genomic applications in practice and prevention (EGAPP): implementation and evaluation of a model approach. Centers for Disease Control and Prevention (CDC). Available at: http://www.cdc.gov/genomics/gtesting/egapp.htm Accessed June 15, 2007.
7. United Kingdom Genetic Testing Network (UKGTN). National Health Service (NHS). Available at: http://www.genetictestingnetwork.org.uk/gtn/ Accessed June 15, 2007.
8. Secretary's Advisory Committee on Genetic Testing. Development of a classification methodology for genetic tests: conclusions and recommendations of the Secretary's Advisory Committee on genetic testing. September 2001. National Institutes of Health (NIH). Available at: http://www4.od.nih.gov/oba/sacgt/ reports/Addendum_final.pdf Accessed June 15, 2007.
9. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001; 108:972-982.
10. Skinner MA, Moley JA, Dilley WG, Owzar K, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113.
11. Lindor NM, Peterson GM, Hadley DW, Kinney AY, et al. Recommendations for the care of individuals with an inherited predisposition to cancer: Lynch syndrome (hereditary nonpolyposis colorectal cancer). JAMA 2006;296:15-7-17.
12. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000;24:137-142.
13. Grosse S, Khoury MJ, Greene CL, Crider KS, et al. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 2006;8:205-212.
14. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-2293.
15. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698.
16. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler Thromb Vasc Biol 2004;24:628-636.
17. Visvikis-Siest S, Marteau JB. Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol 2006;17:139-151.
18. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-323.
19. Willer CJ, Bonnycastle LL, Conneely KN, Duren WL, et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 2007;56:256-264.
20. Darras BT, Korf BR, Urion DK. Dystrophinopathies (GeneReview) 2005. Available at: http://www.genetests.org/servlet/access?id=8888891&db= genetests&fcn= y&dontshowglossarylinks=yes&key= PR8mDHf6q6M3E&filename=/profiles/dbmd/index.html Accessed June 15, 2007.
21. Pagon RA, Daiger SP. Retinitis pigmentosa overview (GeneReview) 2005. Available at: http://www.genetests.org/servlet/access?db=geneclinics&site= gt&id=8888891&key=PR8mDHf6q6M3E&gry=&fcn=y&fw= eV34&filename=/profiles/rp-overview/index.html Accessed June 15, 2007.
22. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 1995;274:1627-1629.
23. McConnell LM, Koenig BA, Greely HT, Raffin TA. Genetic testing and Alzheimer disease: recommendations of the stanford program in genomics, ethics, and society. Genet Test 1999;3:3-12.
24. Post SG, Whitehouse PJ, Binstock RH, Bird TD, et al. The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 1997;277:832-836.
25. Roberts JS, Barber M, Brown TM, Cupples LA, et al. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med 2004;6:197-203.
26. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol 2003;38:107-117.
27. Gogarty B. Parents as partners. Cambridge Genetics Knowledge Park, 2005. Available at: http://www.phgfoundation.org/pages/serviceprojects.htm#ld Accessed June 15, 2007.
28. Gutmann A, Thompson D. Just deliberation about health care. In: Danis M, Clancy C, Churchill LR, editors. Ethical dimensions of health policy. New York: Oxford University Press, 2002.
29. Wald NJ, Hackshaw AK. Advances in antenatal screening for Down syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:563-580.
30. Kaback MM. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000;159:S192-S195.
31. Cao A, Rosatelli MC, Monni G, Galanello R. Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am 2002;29:305-328.
32. Weil J, Ormond K, Peters J, Peters K, et al. The relationship of non-directiveness to genetic counseling: report of a workshop at the 2003 NGSC annual education conference. J Genet Couns 2006;15:85-94.
33. Press N, Browner CH. Why women say yes to prenatal diagnosis. Soc Sci Med 1997; 45:979-989.
34. Parens E, Asch A. Disability rights critique of prenatal genetic testing: reflections and recommendations. Ment Retard Dev Disabil Res Rev 2003;9:40-47.
35. Kearns WG, Pen R, Graham J, Han T, et al. Preimplantation genetic diagnosis and screening. Semin Reprod Med 2005;23:336-347.
36. Braude P. Preimplantation diagnosis for genetic susceptibility. N Engl J Med 2006; 355:541-543.
37. Katz MG, Fitzgerald L, Bankeir A, Savulescu J, et al. Issues and concerns of couples presenting for preimplantation genetic diagnosis (PGD). Prenat Diagn 2002; 22: 1117-1122.
38. Haigh B, Huk M, Hayden MR. Huntington disease (GeneReview) 2005. Available at: http://www.genetests.org/servlet/access?db=geneclinics&site= gt&id=8888891&key=PR8mDHf6q6M3E&gry=&fcn=y&fw= ZnUi&filename=/profiles/huntington/index.html Accessed June 15, 2007.
39. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 2004;140:330-337.
40. Burke W, Coughlin SS, Lee NC, Weed DL, et al. Application of population screening principles to genetic screening for adult-onset conditions. Genet Test 2001;5:201-211.
41. Sieving PA, Collins FS. Genetic ophthalmology and the era of clinical care. JAMA 2007;297:733-736.
42. Schaumberg DA, Hankinson SE, Guo Q, Rimm E, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol 2007;125:55-62.
43. Bossuyt PM, Irwig L, Crane L, Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ 2006;332:1089-1092.
44. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285: 1987-1991.
45. Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet Med 2005;7:519-523.